作者: Roberto Latini , Serge Masson , Noeleen de Angelis , Inder Anand
DOI: 10.1054/JCAF.2002.0805288
关键词: Natriuretic peptide 、 Management of heart failure 、 Clinical trial 、 Medicine 、 Valsartan 、 Intensive care medicine 、 Heart disease 、 Internal medicine 、 Brain natriuretic peptide 、 Ventricular remodeling 、 Heart failure 、 Cardiology 、 Cardiology and Cardiovascular Medicine
摘要: Background: Progression of heart failure is related to ventricular remodeling, a process associated neurohormonal activation. Brain natriuretic peptide (BNP), member the family, has recently emerged as an important neurohormone in pathophysiology failure. Methods: In this update, some recent advances on role BNP are summarized. particular, diagnosis disease, prognostic marker cardiovascular events and possible guide optimize therapy discussed. Results: Recent results from 4,300 patients enrolled Valsartan Heart Failure Trial (Val-HeFT) confirmed that strongest predictor outcome failure, when compared other neurohormones clinical markers. The current use screening its future roles presented. Conclusion: years, there been impressive accumulation data supporting diagnostic Development rapid, accurate affordable methods will allow routine monitoring wide spectrum settings, general practice controlled trials.